AstraZeneca’s CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing ...

Pharmaceutical CEOs are on notice about sky-high drug prices as President Donald Trump demands a recalibration of what ...

AstraZeneca's efforts are paying off as strong U.S. demand, and robust sales of newer cancer, heart and kidney disease ...

AstraZeneca Plc’s chief executive officer broke ranks with his pharmaceutical industry peers Tuesday, saying he was open to ...

With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...

President Donald Trump has given major pharmaceutical companies 60 days to slash prescription drug prices or face action.

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

Plus: All the news and watercooler chat from Fortune.

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

In an earnings call on July 29th, in which the company reported a 13% increase in half-year profits, he said about Britain ...

Speaking from Astra's offices in New York, Sir Pascal Soriot (pictured) said it was 'global', but it was 'very much rooted ...

Markets reflect a widespread belief that the US president always chickens out on trade measures. AstraZeneca’s plan to invest ...